74 related articles for article (PubMed ID: 19081178)
21. Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response.
Takahashi A; Matsumoto H; Ohnishi T
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):550-8. PubMed ID: 18410999
[TBL] [Abstract][Full Text] [Related]
22. Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3.
Funston G; Goh W; Wei SJ; Tng QS; Brown C; Jiah Tong L; Verma C; Lane D; Ghadessy F
PLoS One; 2012; 7(8):e42642. PubMed ID: 22912717
[TBL] [Abstract][Full Text] [Related]
23. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
24. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts.
Latonen L; Taya Y; Laiho M
Oncogene; 2001 Oct; 20(46):6784-93. PubMed ID: 11709713
[TBL] [Abstract][Full Text] [Related]
25. Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression.
Narasimhan M; Rose R; Karthikeyan M; Rathinavelu A
Life Sci; 2007 Oct; 81(17-18):1362-72. PubMed ID: 17931661
[TBL] [Abstract][Full Text] [Related]
26. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
27. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
[TBL] [Abstract][Full Text] [Related]
28. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
29. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
30. Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.
Morgado-Palacin L; Llanos S; Urbano-Cuadrado M; Blanco-Aparicio C; Megias D; Pastor J; Serrano M
Carcinogenesis; 2014 Dec; 35(12):2822-30. PubMed ID: 25344835
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
33. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability.
Dias CS; Liu Y; Yau A; Westrick L; Evans SC
Cancer Res; 2006 Oct; 66(19):9467-73. PubMed ID: 17018602
[TBL] [Abstract][Full Text] [Related]
34. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
35. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.
Sui X; Shin S; Zhang R; Firozi PF; Yang L; Abbruzzese JL; Reddy SA
Oncogene; 2009 Feb; 28(5):709-20. PubMed ID: 19029954
[TBL] [Abstract][Full Text] [Related]
36. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.
Ohkubo S; Tanaka T; Taya Y; Kitazato K; Prives C
J Biol Chem; 2006 Jun; 281(25):16943-16950. PubMed ID: 16624812
[TBL] [Abstract][Full Text] [Related]
37. HDM2-binding partners: interaction with translation elongation factor EF1alpha.
Frum R; Busby SA; Ramamoorthy M; Deb S; Shabanowitz J; Hunt DF; Deb SP
J Proteome Res; 2007 Apr; 6(4):1410-7. PubMed ID: 17373842
[TBL] [Abstract][Full Text] [Related]
38. The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma.
Tang J; Shi H; Li H; Zhen T; Dong Y; Zhang F; Yang Y; Han A
Tumour Biol; 2016 Aug; 37(8):10287-301. PubMed ID: 26842923
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of p53 in cells expressing hepatitis B virus X-protein involves p53 phosphorylation and a reduction of Hdm2.
Wang JH; Yun C; Kim S; Chae S; Lee YI; Kim WH; Lee JH; Kim W; Cho H
Cancer Sci; 2008 May; 99(5):888-93. PubMed ID: 18294283
[TBL] [Abstract][Full Text] [Related]
40. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.
Kocik J; Machula M; Wisniewska A; Surmiak E; Holak TA; Skalniak L
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31331108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
